➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Harvard Business School
Moodys
Baxter
Johnson and Johnson

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CRIZOTINIB

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Crizotinib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00939770 ↗ Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Active, not recruiting National Cancer Institute (NCI) Phase 1/Phase 2 2009-09-01 RATIONALE: Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of crizotinib and to see how well it works in treating young patients with relapsed or refractory solid tumors or anaplastic large cell lymphoma.
NCT00939770 ↗ Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Active, not recruiting Children's Oncology Group Phase 1/Phase 2 2009-09-01 RATIONALE: Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of crizotinib and to see how well it works in treating young patients with relapsed or refractory solid tumors or anaplastic large cell lymphoma.
NCT01082380 ↗ Radiolabeled [14C]PF-02341066 Study To Investigate The Absorption, Metabolism And Excretion In Healthy Male Volunteers Completed Pfizer Phase 1 2010-03-01 The rationale for this study is to investigate the absorption, metabolism and excretion of [14C]PF 02341066 and characterize plasma, fecal and urinary radioactivity, and identify any metabolites, if possible, of [14C]PF 02341066 in humans.
NCT01121588 ↗ An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK) Active, not recruiting Pfizer Phase 1 2011-03-01 This is a Phase 1 trial evaluating the safety and efficacy of crizotinib in patients with tumors except non-small cell lung cancer that are positive for ALK.
NCT01125904 ↗ A Study To Investigate The Taste Of Crizotinib Liquid In Trained Healthy Adult Volunteers Completed Pfizer Phase 1 2010-06-01 An oral-liquid, pediatric form of crizotinib designed for use by pediatric patients is being tested for its' palatability in adults.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Crizotinib

Condition Name

Condition Name for Crizotinib
Intervention Trials
Non-Small Cell Lung Cancer 25
Healthy 10
Carcinoma, Non-Small-Cell Lung 8
Lung Cancer 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Crizotinib
Intervention Trials
Carcinoma, Non-Small-Cell Lung 64
Lung Neoplasms 54
Lymphoma 17
Neoplasms 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Crizotinib

Trials by Country

Trials by Country for Crizotinib
Location Trials
United States 624
China 80
Italy 78
Japan 63
Spain 50
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Crizotinib
Location Trials
California 30
Texas 30
Massachusetts 27
Florida 25
Pennsylvania 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Crizotinib

Clinical Trial Phase

Clinical Trial Phase for Crizotinib
Clinical Trial Phase Trials
Phase 4 3
Phase 3 17
Phase 2/Phase 3 1
[disabled in preview] 73
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Crizotinib
Clinical Trial Phase Trials
Recruiting 57
Not yet recruiting 36
Active, not recruiting 25
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Crizotinib

Sponsor Name

Sponsor Name for Crizotinib
Sponsor Trials
Pfizer 50
National Cancer Institute (NCI) 15
Hoffmann-La Roche 9
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Crizotinib
Sponsor Trials
Other 132
Industry 108
NIH 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Colorcon
McKinsey
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.